Preoperative chemoradiation with raltitrexed ('Tomudex') for T2/N+ and T3/N+ rectal cancers: A phase I study

European Journal of Cancer

Volumn 37, Issue 16, 2001, Pages 2050-2055

  Valentini, V ^a   Doglietto, G B ^a   Morganti, A G ^a   Turriziani, A ^a   Smaniotto, D ^a   De Santis, M ^a   Ratto, C ^a   Sofo, L ^a   Cellini, N ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Preoperative radiotherapy; Raltitrexed; Recommended dose; Rectal cancer; Toxicity

Indexed keywords

RALTITREXED;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; LEUKOPENIA; LIVER TOXICITY; MALE; PHASE 1 CLINICAL TRIAL; PREOPERATIVE RADIOTHERAPY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RADIATION DOSE; RECTUM CARCINOMA; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; QUINAZOLINES; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; THIOPHENES;

EID: 0034773727     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00247-7     Document Type: Article

References (42)

1. Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes' B and C rectal cancer
2. Effective surgical adjuvant therapy for high-risk rectal carcinoma
3. Prolongation of the disease-free interval in surgically treated rectal carcinoma
4. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer
5. Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum
6. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery
7. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: Initial results of intergroup 0114
8. Which 5-fluorouracil regimen - The great debate
9. Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum
10. Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin and concurrent radiation therapy for clinically resectable T3 rectal cancer
11. Preoperative infusional chemoradiation therapy for stage T3 rectal cancer
12. Preoperative chemoradiation for extraperitoneal T3 rectal cancer: Acute toxicity, tumor response and sphincter preservation
13. Preoperative chemoradiation with CDDP and 5-FU for extraperitoneal T3 rectal cancer: Acute toxicity, tumor response, sphincter preservation
14. Integrated treatment with doxifluridine and radiotherapy in recurrent or primary unresectable rectal cancer. A feasibility study
15. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study
16. Mature results from three large controlled studies with raltitrexed ('Raltitrexed')
17. ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer
18. Folate-based thymidylate synthase inhibitors as anticancer drugs
19. 'Tomudex' (ZD1694) results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia
20. Interaction of Tomudex with radiation in vitro and in vivo
21. Control of small bowel motion and set up errors during box pelvic treatment, using the new 'Up Down Table' device
22. Reporting result of cancer treatment
23. Overview
24. The experience of diagnostic and therapeutic integration in rectal cancer. Preliminary notes
25. 'Tomudex' (raltitrexed) plus radiotherapy as post-operative treatment or palliative treatment for patients with rectal cancer: Phase I studies
26. Combined modality therapy of rectal cancer: Decreased acute toxicity with the preoperative approach
27. Qualitative and chronological assessment of toxicities during treatment with raltitrexed ('Tomudex') in 861 patients: Implications for patient management
28. Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma. A report of surgical morbidity
29. The effect of combined modality therapy on local control and survival
30. The development of chemotherapy drugs as radiosensitizers: An overview
31. Concomitant chemoradiotherapy: Rationale and clinical experience in patients with solid tumors
32. Combined effect of x radiation and 5-fluorouracil on survival of transplanted leukemic cells
33. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-Fluorouracil or Ftorafur and X Rays
34. Phase I and pharmacologic study of 72-hour infused 5-Fluorouracil and hyperfractionated cyclical radiation
35. Theoretical basis and clinical applications of 5-fluorouracil as a radiosensitizer - An overview
36. Clinical pharmacokinetics of fluorouracil and folinic acid
37. Controversial issues in 5-fluorouracil infusion use. Dose intensity, treatment duration and cost comparisons
38. Phase I study of 5-Fluorouracil administered by protracted venous infusion, leucovorin, and pelvic radiation therapy
39. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors
40. Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients